Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy

Radiation Medicine - Medical Imaging and Radiation Oncology

Volumn 20, Issue 4, 2002, Pages 181-186

  Nakamura, Ryuji ^a   Obara, Toya ^a   Katsuragawa, Shigehiko ^a   Tamakawa, Yoshiharu ^a   Koeda, Keisuke ^a   Ikeda, Kenichiroh ^a   Sato, Nobuhiro ^a   Ishida, Kaoru ^a   Shozushima, Masanori ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Esophageal cancer; Positron emission tomography; Residual disease

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; ESOPHAGOSCOPY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036656780     PISSN: 02882043     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Vogel SB, Mendenhall WM, Sombeck MD, et al. Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg, 221: 685-695, 1995.
2. Ganem G, Dubray B, Raoul Y, et al. Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus. J Clin Oncol, 15: 701-711, 1997.
3. Tsujinaka T, Shiozaki H, Kido Y, et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy for inoperable squamous cell carcinoma of the esophagus potentially followed by surgery. J Surg Oncol, 58: 50-56, 1998.
4. Hennequin C, Gayet B, Sauvanet A, et al. Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus. Int J Radiat Oncol Biol Phys, 49: 657-664, 2001.
5. Mandard A, Dalibard F, Mandard J, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer, 73: 2680-2686, 1994.
6. Akakura I, Nakamura Y, Kakegawa T, et al. Surgery of carcinoma of the esophagus with preoperative radiation. Chest, 57: 47-57, 1970.
7. 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol, 168: 417-424, 1997.
8. Choi JY, Lee KH, Shim YM, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med, 41: 808-815, 2000.
9. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med, 23: 1409-1415, 1996.
10. Beahs OH, Henson DE, Hutter RV, Kennedy BJ. Esophagus. In Manual for Staging of Cancer, 4th ed. (American Joint Committee on Cancer eds.; JB Lippincott, Philadelphia) pp. 75-79, 1993.
11. Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Clin Nucl Med, 21: 941-949, 1996.
12. Torizuka T, Zasadny KR, Recker B, Wahl RL. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetics rate constants and findings of in vitro studies. Radiology, 207: 767-774, 1998.
13. Bjorn LDM, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg, 233: 300-309, 2001.
14. 18F-FDG PET imaging for differentiating malignant from inflammatory process. J Nucl Med, 42: 1412-1417, 2001.